Paul Edwards Posted June 3, 2016 Share Posted June 3, 2016 This may be a drug to watch in the future. Seviteronel (VT-464) is a once-daily oral therapeutic given without prednisone. Seviteronel selectively inhibits CYP17 lyase, a target of abiraterone, and has unique blocking effects on the androgen receptor (AR), the target of enzalutamide. There is a growing body of preclinical and clinical evidence that shows that some abiraterone- or enzalutamide-resistant patients will respond to seviteronel treatment. Currently there are phase II clinical trials of seviteronel in the US and Europe. At the moment there are not any clinical trials of this drug in Australia. In January 2016 the United States Food and Drug Administration (FDA) granted Fast Track Designation for seviteronel for the treatment of patients with metastatic castrate-resistant prostate cancer. The Fast Track program is designed to facilitate the development and review of drugs intended to treat serious conditions and fill an unmet medical need. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.